VEGF targeted therapy, including bevacizumab, which is the humanized antibody for VEGF‐A, offers clinical benefits to patients with several types of cancer including colon cancer, breast cancer, and NSCLC. This evidence concerns the gene VEGFA and colonic neoplasm.